Center for Individualized Medicine

Breast Cancer: PROMISE Study

The PROMISE study is designed to obtain state-of-the-art tumor sequencing information and to develop patient-derived xenografts in women with metastatic hormone receptor-positive breast cancer treated with palbociclib (Ibrance) and endocrine therapy. Other aims are to discover microbiome-based biomarkers of treatment response, to evaluate drug response phenotypes using fresh tumor 3D microcancer models and to identify metabolite biomarkers of response.

Breast Cancer: STRIVE Study

The STRIVE Study was designed to evaluate a new test for the detection of multiple early-stage cancers, when the chance for cure is greater. A blood test that identifies genetic material from a developing tumor may assist in finding cancers that are not easily detected by standard cancer-screening methods, or that have no existing screening paradigm in current practice. When applied to breast cancer, it may be possible to combine the blood test with mammography to improve detection of breast cancer.

Breast Cancer (Chemotherapy-Resistant): BEAUTY2 Study

The BEAUTY2 study is designed to test new drugs for women with chemotherapy-resistant breast cancer. At this time, there are limited options for women with residual cancer after neoadjuvant chemotherapy. The goal of the BEAUTY2 study is to accelerate drug development for patients with chemotherapy-resistant breast cancer.

Cancer and aggressive tumors: Ex Vivo Study

The Ex Vivo study is developing an innovative strategy for using genomics and human tumor samples as guides to treat advanced cancer and other aggressive tumors. Researchers create a miniature replica of each participant’s tumor, conduct a comprehensive genomic analysis of the tumor cells and use the replica for testing therapies outside the patient’s body. The Ex Vivo study centers on finding treatment options by knowing the full story of each tumor and recognizing every patient’s illness as a unique case of altered cells.

Cancer Immunotherapy: IMPRESS Study

The IMPRESS Study seeks to discover and verify new tissue- and blood-based markers for response and monitoring in all cancers for which immunotherapy has shown clinical benefit to patients.

Cardiovascular Disease: TAILOR-PCI Study

The TAILOR-PCI study used genetic information to find the best medication for patients who undergo coronary angioplasty, also known as percutaneous coronary intervention.

Up to 30% of patients receiving angioplasty have a genetic variant thought to interfere with their ability to metabolize standard antiplatelet medications. Alternative drugs exist, and this study investigated whether physicians should prescribe medication based on genotype.

Genomic Sequencing: Tapestry Study

The Tapestry Study seeks to understand the short-term and long-term impact of genetic testing on people's healthcare when their DNA results are part of the electronic health record.

The goal of this study is to provide patients with clinically actionable genetic findings.

Hematologic Cancer: EXTEND Biomarker Study

The EXTEND Study collects and analyzes biospecimens from patients receiving CAR-T cell therapy for B-cell acute leukemia or aggressive non-Hodgkin lymphoma. The goal of the study is to discover biomarkers that could guide development of new treatment strategies and help clinicians choose the best therapy for the patient in the event of relapse.

Major Depressive Disorder: ALMOND Study

The ALMOND Study evaluates a novel artificial intelligence algorithm to help identify effective personalized treatments for people diagnosed with major depressive disorder. The algorithm is intended to discover patterns and unique characteristics in participants' genomic data and health histories, allowing for the right treatment to be chosen to achieve a therapeutic benefit.

Pharmacogenomics: RIGHT 10K Study

In the RIGHT 10K Study, researchers embedded the genetic information of 10,000 Mayo Clinic Biobank participants in the electronic health record to see if doing so improves long-term outcomes for both the patient and the healthcare delivery system at large. Clinicians treating patients in the study can act on this information with the help of a drug-gene pair best practice alert system developed at Mayo Clinic.